Stockscreener 앱 받기
245.44
2.75%
6.57
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Sanctuary Advisors LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
City: Taking RNAi beyond the liver - BioCentury
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance
4 Biotech Stocks Most Wall Street Analysts Are Bullish About - Yahoo Finance
Biotech CEO on RNAI and Medicine of the Future - Barron's
RNAi Technology Market to Witness Huge Growth by 2031 | Alnylam - openPR
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by StockNews.com to "Buy" Rating - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: strong data bolsters amvuttra stock outlook - Investing.com
Gene Therapy Market Key Players AnalysisNovartis Ag, Biogen - openPR
What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You - Simply Wall St
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update - MarketBeat
Toronto Dominion Bank Acquires 3,315 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam's SWOT analysis: strong helios-b data bolsters amvuttra stock outlook - Investing.com India
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Boosted by Tidal Investments LLC - MarketBeat
Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells 1,752 Shares of Stock - MarketBeat
Geode Capital Management LLC Acquires 66,928 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Kovitz Investment Group Partners LLC Acquires New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam's Onpattro Drug Uses Patented UTexas Tech, Suit Says (1) - Bloomberg Law
Where are the Opportunities in (ALNY) - Stock Traders Daily
Public Employees Retirement System of Ohio Sells 3,275 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Bleeding Disorders Treatment Market Emerging Trends and Growth - openPR
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Nomura Asset Management Co. Ltd. - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CAMP4 Therapeutics Taps Former Alnylam CEO, RNA Pioneer to Drive Next-Gen Gene Therapy Platform - StockTitan
Groupama Asset Managment Sells 2,849 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
FAP therapy nucresiran safely reduces TTR in healthy people: Trial - FAP News Today
RNAi Therapeutics and Technology Market Top Players -Alnylam, - openPR
Two Sigma Advisers LP Sells 155,600 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
AL Amyloidosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Janssen Pharma, Prothena, Alexion Pharma, Alnylam Pharma, Attralus, Neurimmune AG - The Globe and Mail
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Janus Henderson Group PLC Has $60.32 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Decreased by HighTower Advisors LLC - MarketBeat
Oligonucleotide Therapy Market Key Players AnalysisBPCI - openPR
Dyslipidemia Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Investment Management Corp of Ontario - MarketBeat
Royal London Asset Management Ltd. Has $76.94 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Small Interfering RNA (siRNA) Therapeutics Market Key Players - openPR
What Makes Alnylam (ALNY) a New Buy Stock - Yahoo Finance
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Parkman Healthcare Partners LLC Invests $7.01 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat
16,510 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Erste Asset Management GmbH - MarketBeat
Bridgewater Associates LP Acquires New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now? - Yahoo Finance
PDT Partners LLC Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Bellevue Group AG Sells 110,739 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Eventide Asset Management LLC Buys 137,333 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (FRA:DUL) EBIT : €-170 Mil (TTM As of Sep. 2024) - GuruFocus.com
Cerity Partners LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Suvretta Capital Management LLC Has $3.80 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
The Manufacturers Life Insurance Company Decreases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Antisense & RNAi Therapeutics Global Market Report 2024 To 2033 | - openPR
Alnylam Pharmaceuticals CEO sells $1.31 million in stock By Investing.com - Investing.com South Africa
Penserra Capital Management LLC Sells 8,414 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals CMO Pushkal Garg sells $422,144 in stock - Investing.com India
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use - MSN
Alnylam Pharmaceuticals CSO sells $754,945 in stock By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals CSO sells $754,945 in stock - Investing.com India
Alnylam Pharmaceuticals EVP Tanguler sells $368,685 in stock - Investing.com India
Alnylam Pharmaceuticals CEO sells $1.31 million in stock - Investing.com India
Alnylam Pharmaceuticals CFO sells $422,144 in stock - Investing.com
Alnylam Pharmaceuticals EVP Tanguler sells $368,685 in stock By Investing.com - Investing.com UK
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference - BioSpace
1.56%
0.35%
자본화:
|
볼륨(24시간):